Clinical Trial Update: Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Custodiol-HTK solution as a cardioplegic agent in patients with coronary artery disease and myocardial ischemia, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Myocardial Ischemia

Drugs mentioned

• Custodiol-HTK (Histidine-tryptophan-ketoglutarate) solution (Histidine-tryptophan-ketoglutarate solution)

Snippet

Sponsor: Marc Sakwa, MD | Conditions: Coronary Artery Disease, Myocardial Ischemia | Phase 2 | Status: COMPLETED | Results posted: 2017-03-01